Arcutis had a productive first quarter of 2021, with positive Phase 3 results for topical roflumilast cream in plaque psoriasis and progress in advancing topical roflumilast foam into Phase 3 development for scalp psoriasis and seborrheic dermatitis. The company's Phase 1/2b study of ARQ-252 in chronic hand eczema did not meet its primary endpoint. Arcutis ended the quarter with a strong financial position, holding over $440 million in cash, cash equivalents, and marketable securities.